Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 91600.0
(-0.76%)
KRW 91600.0
(-0.76%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 655.34 Billion KRW | 20.77% |
| 2022 | 542.63 Billion KRW | 9.44% |
| 2021 | 495.81 Billion KRW | 1.37% |
| 2020 | 489.13 Billion KRW | 20.99% |
| 2019 | 404.27 Billion KRW | 6.28% |
| 2018 | 380.4 Billion KRW | 5.77% |
| 2017 | 359.65 Billion KRW | 7.4% |
| 2016 | 334.88 Billion KRW | 13.07% |
| 2015 | 296.18 Billion KRW | 5.65% |
| 2014 | 280.34 Billion KRW | 506.38% |
| 2013 | 46.23 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 138.92 Billion KRW | 13.25% |
| 2024 Q1 | 122.67 Billion KRW | -46.86% |
| 2023 Q3 | 149.82 Billion KRW | 3.79% |
| 2023 Q4 | 230.84 Billion KRW | 54.08% |
| 2023 FY | 655.34 Billion KRW | 20.77% |
| 2023 Q1 | 135.47 Billion KRW | -4.88% |
| 2023 Q2 | 144.34 Billion KRW | 6.55% |
| 2022 Q3 | 140.36 Billion KRW | 4.31% |
| 2022 Q2 | 134.55 Billion KRW | 7.39% |
| 2022 Q1 | 125.29 Billion KRW | 0.71% |
| 2022 FY | 542.63 Billion KRW | 9.44% |
| 2022 Q4 | 142.42 Billion KRW | 1.47% |
| 2021 Q1 | 112.98 Billion KRW | -13.05% |
| 2021 Q2 | 129.77 Billion KRW | 14.87% |
| 2021 Q3 | 128.64 Billion KRW | -0.87% |
| 2021 Q4 | 124.41 Billion KRW | -3.28% |
| 2021 FY | 495.81 Billion KRW | 1.37% |
| 2020 Q1 | 104.05 Billion KRW | -7.37% |
| 2020 Q3 | 135.19 Billion KRW | 12.72% |
| 2020 Q4 | 129.94 Billion KRW | -3.89% |
| 2020 Q2 | 119.94 Billion KRW | 15.27% |
| 2020 FY | 489.13 Billion KRW | 20.99% |
| 2019 Q2 | 101.68 Billion KRW | 15.75% |
| 2019 FY | 404.27 Billion KRW | 6.28% |
| 2019 Q4 | 112.33 Billion KRW | 9.69% |
| 2019 Q3 | 102.4 Billion KRW | 0.71% |
| 2019 Q1 | 87.85 Billion KRW | -13.97% |
| 2018 Q3 | 96.2 Billion KRW | -0.46% |
| 2018 Q4 | 102.11 Billion KRW | 6.13% |
| 2018 FY | 380.4 Billion KRW | 5.77% |
| 2018 Q2 | 96.65 Billion KRW | 13.14% |
| 2018 Q1 | 85.43 Billion KRW | -14.5% |
| 2017 Q1 | 84.37 Billion KRW | 0.0% |
| 2017 FY | 359.65 Billion KRW | 7.4% |
| 2017 Q2 | 84.35 Billion KRW | -0.03% |
| 2017 Q3 | 91 Billion KRW | 7.88% |
| 2017 Q4 | 99.92 Billion KRW | 9.8% |
| 2016 Q1 | 81.94 Billion KRW | 5.52% |
| 2016 Q2 | 85.81 Billion KRW | 4.73% |
| 2016 Q3 | 85.43 Billion KRW | -0.44% |
| 2016 Q4 | - KRW | -100.0% |
| 2016 FY | 334.88 Billion KRW | 13.07% |
| 2015 FY | 296.18 Billion KRW | 5.65% |
| 2015 Q4 | 77.65 Billion KRW | 0.59% |
| 2015 Q3 | 77.19 Billion KRW | 6.88% |
| 2015 Q2 | 72.22 Billion KRW | 4.53% |
| 2015 Q1 | 69.09 Billion KRW | -5.74% |
| 2014 Q1 | 67.31 Billion KRW | 0.0% |
| 2014 FY | 280.34 Billion KRW | 506.38% |
| 2014 Q2 | 75.49 Billion KRW | 12.16% |
| 2014 Q3 | 64.22 Billion KRW | -14.94% |
| 2014 Q4 | 73.3 Billion KRW | 14.15% |
| 2013 FY | 46.23 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -1309.188% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | -79.986% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -229.506% |
| HANDOK Inc. | 151.36 Billion KRW | -332.952% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -874.858% |
| Yuhan Corporation | 564.5 Billion KRW | -16.091% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | -103.389% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -2659.683% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 21.596% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -773.331% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -229.382% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -1512.178% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -593.372% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -365.259% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -1309.188% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -1787.74% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -753.109% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 5540.52% |
| JW Holdings Corporation | 446.15 Billion KRW | -46.886% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | -215.769% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -95.233% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -733.561% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -771.027% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -807.533% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -256.525% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -1309.188% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | -122.061% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 3.845% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -95.233% |
| Yuhan Corporation | 564.5 Billion KRW | -16.091% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | -224.714% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -823.812% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -561.782% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -95.233% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -349.2% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -277.746% |
| CKD Bio Corp. | 5.01 Billion KRW | -12979.927% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | -157.774% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -255.924% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -567.864% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -733.561% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | -76.406% |
| Boryung Corporation | 333.26 Billion KRW | -96.641% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -1209.496% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -229.382% |
| JW Lifescience Corporation | 51.32 Billion KRW | -1176.852% |